Related Experiment Videos
Chemotherapy for retinoblastoma.
Helen S L Chan1, Brenda L Gallie, Francis L Munier
1Division of Hematology/Oncology, Department of Pediatrics, Institute of Medical Science, University of Toronto, Ontario, Canada. hslchan@attglobal.net
Ophthalmology Clinics of North America
|March 15, 2005
Summary
Chemotherapy can shrink intraocular retinoblastoma in children but requires focal therapy to cure the eye cancer. Combined treatments are essential for managing this common childhood malignancy.
Area of Science:
- Pediatric Oncology
- Ophthalmology
- Medical Research
Background:
- Retinoblastoma is the most frequent pediatric eye cancer.
- Intraocular retinoblastoma treatment has explored various chemotherapy regimens.
- Chemotherapy combinations often include carboplatin, etoposide, or teniposide, sometimes with vincristine and cyclosporine.
Purpose of the Study:
- To review pilot studies on chemotherapy for intraocular retinoblastoma.
- To assess the role of chemotherapy in combination with focal therapy.
- To understand the necessity of consolidation treatments for retinoblastoma.
Main Methods:
- Review of pilot studies utilizing different chemotherapy agents (carboplatin, etoposide, teniposide).
- Analysis of treatment protocols involving varying dosages, schedules, and durations.
- Evaluation of consolidation strategies including focal therapies (photocoagulation, thermotherapy, cryotherapy, brachytherapy) and radiation.
Main Results:
- Chemotherapy effectively reduces tumor size in intraocular retinoblastoma.
- Chemotherapy alone does not provide a cure for retinoblastoma.
- Consolidation with focal therapy is a critical component of successful treatment.
Conclusions:
- Combined chemotherapy and focal therapy are necessary for treating intraocular retinoblastoma.
- Focal therapies are essential to consolidate the response achieved by chemotherapy.
- Multidrug resistance may be counteracted with agents like cyclosporine in specific regimens.